

Special Issue

Recent Advances in Cardiovascular Drug Discovery and Development

Message from the Guest Editors

The therapeutic management of cardiac diseases is changing rapidly. While at the end of the 20th century, mainly symptomatic therapies were dominant, in recent years activities aimed at modifying the metabolism of cells or influencing more and more interesting signalling pathways have become the attitude. As new discoveries are made, new options are introduced into routine clinical management. At the same time, there are new challenges, for example, better options for patients treated for heart failure or completely new problems, such as the need to treat complications after COVID-19 infection. In such a situation, a significant acceleration of the search for new indications for known drugs, and new more effective as-yet-unknown indications, new pathways, and modulating agents that may be beneficial in therapy. Thus, research activities begin with molecular chemistry and end with evaluation in randomized clinical trials. Hence, the purpose of this Special Issue of *Molecules* is to gather knowledge and advancements including clinical, translational, and preclinical evaluations of active cardiovascular compounds.

Guest Editors

Prof. Dr. Grzegorz Grzešek


Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland

Prof. Dr. Alicja Nowaczyk

Department of Organic Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland

Deadline for manuscript submissions

closed (31 January 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/116916

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).